Given the similar complexity of blood and tumor lysate as sample matrices, and our success in quantifying soluble protein analytes from blood with the D4 assay, we hypothesized that a D4 assay for HER2 should be able to quantify the receptor expression level from crude lysate generated from breast tumor cells without any further processing. The gene discussed is ERBB2; the disease is neoplasm.